The object of B lymphocyte development is to produce cells with a diverse group of clonally restricted antigen receptors that are not self reactive ([@B1]). Antigen receptor diversification is achieved through regulated genomic rearrangements that result in the random assembly of Ig gene segments into productive transcription units ([@B2], [@B3]). These gene rearrangements are in large part regulated by the preB cell receptor (BCR)^1^.

B cells undergoing Ig heavy chain gene rearrangements (pre-B) can express at least two types of BCRs. One form of the receptor is composed of membrane immunoglobulin heavy chain (mIgμ), λ5, V--pre-B, and Igα-Igβ, and is referred to as the pre-BCR ([@B4]--[@B6]). A second form of the preB cell receptor, known as the Dμ pre-BCR ([@B7]), is found only in pre-B1 cells ([@B8]) and contains truncated mIgμ chains lacking a V~H~ domain (mDμ). mDμ is produced by Ig genes that have rearranged DJ~H~ gene segments in reading frame (RF) 2 producing an in-frame start codon and a truncated transcription unit ([@B7]). Like authentic mIgμ, mDμ is a membrane protein that forms a complex with λ5, V--pre-B, and Igα-Igβ, and in tissue culture cell lines the Dμ pre-BCR can activate cellular signaling responses ([@B9]--[@B14]). But despite its ability to activate nonreceptor tyrosine kinases, Dμ preBCR producing pre-B cells are selected against by a process that is mediated through the transmembrane domain of the mDμ protein ([@B15]). In contrast, pre-B cells that express intact mIgμ containing pre-BCRs are positively selected. Counterselection is reflected in the relative lack of mature B cells that express mIgμ in RF2 ([@B15]--[@B17]). The mechanism by which mDμ activates counterselection has not been defined, but is known to require expression of syk ([@B18]). Here we report on experiments showing that Igβ is essential for counterselection against mDμ in vivo.

Materials and Methods
=====================

Mice.
-----

Igβ^−/−^, mIgμ, and Bcl-2 transgenic strains have been previously described and were maintained by backcrossing with BALB/c mice under specific pathogen-free conditions ([@B19]--[@B21]). All experiments were performed with 4--8-wk-old female mice.

Fluorescence Analysis and Cell Sorting.
---------------------------------------

Single cell suspensions prepared from bone marrow or spleen were stained with PE-labeled anti-B220 and FITC-labeled anti-CD43 (PharMingen, San Diego, CA) or FITC-labeled anti-IgM, and analyzed on a FACScan^®^. For cell sorting, bone marrow cells from four to six mice were stained with the same reagents and separated on a FACSvantage^®^. CD43^+^B220^−^ and CD43^+^B220^+^ cells were collected based on gating with RAG-1^−/−^ controls.

DNA and PCR.
------------

Total bone marrow DNA was prepared for PCR as previously described ([@B22]). DNA from sorted cells was prepared for PCR in agarose plugs ([@B23]). Primers for V~H~--DJ~H~ and D~H~--J~H~ rearrangement were as in reference [@B22]; these primers are mouse specific and do not detect the human Igμ transgene. All experiments were performed a minimum of three times with two independently derived DNA samples. Nonrearranging Ig gene intervening sequences were amplified in parallel with other reactions and used as a loading control ([@B22]). Amplified DNA was visualized after transfer to nylon membranes by hybridization with a 6-kb EcoR1 fragment that spans the mouse J~H~ region.

Isolation and Sequencing of V~H~--DJ~H~ and D~H~--J~H~ Joints.
--------------------------------------------------------------

A J~H~4 primer was combined with either a D~H~ primer or a VHJ558L primer to amplify DJ~H~ and VDJ~H~ rearrangements, respectively. The primers were: (*a*) J~H~4, ACGGATCCGGTGACTGAGGTTCCT; (*b*) D~H~, ACAAGCTTCAAAGCACAATGCCTGGCT; and (*c*) VHJ558L, GCGAAGCTTA(A,G)GCCTGGG(A,G)CTTCAGTGAAG. PCR amplification for DJ~H~ joints was for 35 cycles of 0.5 min at 94°C, and 2 min at 72°C; for VDJ~H~ joints, it was for 0.5 min at 94°C, 1 min at 68°C, and 1.5 min at 72°C. PCR products were purified by agarose gel electrophoresis, subcloned into pBluescript, sequenced using an Applied Biosystems (Foster City, CA) DNA sequencing kit, and analyzed on a genetic analyzer (ABI-310; Applied Biosystems).

Results
=======

mIgM Cannot Induce the Pre-B Cell Transition or Allelic Exclusion in the Absence of Igβ.
----------------------------------------------------------------------------------------

Expression of Igβ is required for B cells to efficiently complete Ig V~H~ to DJ~H~ gene rearrangements ([@B19]). B cells in Igβ^−/−^ mice fail to express normal levels of mIgμ, and B cell development is arrested at the CD43^+^B220^+^ pre-B1 stage ([@B19]). A similar celltype specific developmental arrest is also found in mice that carry a mutation in the transmembrane domain of mIgμ ([@B24]), and mice that fail to complete Ig V(D)J recombination ([@B25]--[@B29]). In view of the abnormally low levels of mIgμ in Igβ^−/−^ mice, failed pre-B cell development might simply be due to lack of Ig expression.

To determine whether mIgμ could induce the pre-B cell transition in the absence of Igβ, we introduced a productively rearranged immunoglobulin gene ([@B20]) into the Igβ^−/−^ background (TG.mμ Igβ^−/−^). We then measured B cell development by staining bone marrow cells with antiCD43 and anti-B220 monoclonal antibodies ([@B30]). We found that expression of a pre-rearranged Ig transgene was not sufficient to activate the pre-B cell transition in the absence of Igβ (Fig. [1](#F1){ref-type="fig"}). TG.mμ Igβ^−/−^ B cells did not develop past the CD43^+^B220^+^ pre-B cell stage (Fig. [1](#F1){ref-type="fig"}). In control experiments, the same mIgμ transgene did induce the appearance of more mature CD43^−^B220^+^ pre-B cells in a RAG^−/−^ mutant background where B cell development was similarly arrested at the CD43^+^B220^+^ stage (20, 25, 26; data not shown). We conclude that in the absence of Igβ, a productively rearranged mIgμ is unable to activate the pre-B cell transition.

Allelic exclusion is established as early as the CD43^+^ B220^+^ stage of B cell development ([@B31]--[@B33]). This early stage of development is found in the bone marrow of Igβ^−/−^ mice ([@B19]). However, we were initially unable to measure allelic exclusion in Igβ mutant mice due to the low efficiency of complete Ig V~H~ to DJ~H~ gene rearrangements and absence of surface Igμ expression ([@B19]). To determine whether expression of mIgμ could activate allelic exclusion in TG.mμ Igβ^−/−^ mice, we measured inhibition of V~H~ to DJ~H~ gene rearrangements by PCR ([@B34]). In controls, the mIgμ transgene inhibited V~H~ to DJ~H~ gene rearrangement ([@B22]), but the same transgene had no effect in the Igβ^−/−^ background (Fig. [2](#F2){ref-type="fig"}). We had previously shown that the cytoplasmic domains of Igα and Igβ are sufficient to activate allelic exclusion ([@B20], [@B35]). The finding that mIgμ is unable to induce allelic exclusion in the absence of Igβ suggests that Igβ is essential for allelic exclusion.

Igβ Is Required for RF2 Counterselection.
-----------------------------------------

Igs with D~H~ joined to J~H~ in RF2 are rarely found in mature B cells ([@B15]--[@B17]). Genetic experiments in mice have shown that counterselection against RF2 requires the transmembrane domain of mIgμ and the syk tyrosine kinase ([@B15], [@B18]). To determine whether counterselection is mediated through Igβ, we sequenced DJ~H~ joints amplified from sorted CD43^+^B220^+^ pre-B cells from Igβ^−/−^ mice and controls. In control samples, only 10% of the DJ~H~ joints were in RF2 (Fig. [3](#F3){ref-type="fig"}), which is in agreement with similar measurements performed in other laboratories ([@B15]--[@B17], [@B31]--[@B33]). In contrast, there was no counterselection in the bone marrow cells of Igβ^−/−^ mice; 13 out of 30 DJ~H~ joints were in RF2 with the remainder being distributed in RF1 and 3 (Fig. [3](#F3){ref-type="fig"}). Thus, in the absence of Igβ, there was no RF2 counterselection at the level of DJ~H~ rearrangements in CD43^+^B220^+^ cells in the bone marrow.

V~H~ to DJ~H~ joining and counterselection are normally completed in CD43^+^B220^+^ pre-B cells ([@B31]--[@B33]), but in Igβ^−/−^ mice, V~H~ to DJ~H~ joining is inefficient ([@B19]). To determine whether RF2 was counterselected in the few Igβ mutant B cells that completed V~H~ to DJ~H~ rearrangements, we amplified and sequenced VHJ558L-DJ~H~4 joints from unfractionated bone marrow cells (Fig. [4](#F4){ref-type="fig"}). As with the DJ~H~ joints, we found no evidence for counterselection against RF2 in VDJ~H~ joints in Igβ^−/−^ B cells. 10/33 VHJ558LDJ~H~4 joints sequenced from Igβ^−/−^ mice were in RF2. By contrast, RF2 was only found in 1 of 11 mature Ig\'s in the controls. The VDJ~H~ and DJ~H~ Igβ^−/−^ joints otherwise resembled the wild type in the number of N and P nucleotides as well as in the extent of nucleotide deletion (Figs. [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). We conclude that there was no selection against RF2 in the absence of Igβ, and that the absence of Igβ has no significant impact on the mechanics of recombination as measured by the variability of the joints.

Discussion
==========

The transmembrane domain of mIgμ is required to produce the signals that mediate several antigen-independent events in developing B cells, including allelic exclusion and the pre-B cell transition ([@B24], [@B36]--[@B39]). However, mIgμ itself is insufficient for signal transduction ([@B40]), and it requires the Igα and Igβ signaling proteins to activate B cell responses in vitro and in vivo.

The earliest developmental checkpoint regulated by IgαIgβ appears to involve either activation of cellular competence to complete V~H~ to DJ~H~ rearrangements, or positive selection for cells that express mIgμ ([@B19]). In the next phase of the B cell pathway, the same transducers are necessary (Fig. [2](#F2){ref-type="fig"}) and sufficient to produce the signals that activate allelic exclusion and the pre-B cell transition ([@B19], [@B20], [@B35], [@B41]). In the present report, we show that in addition to these functions, Igα-Igβ transducers are also necessary for negative selection against Dμ.

Two models have been proposed to explain counterselection against mDμ. The first model states that mDμ is toxic, and that cells expressing this protein are deleted by a mechanism that involves inhibition of proliferation ([@B31]). A second theory postulates that Dμ proteins produce the signal for heavy chain allelic exclusion and block the completion of productive heavy chain gene rearrangements ([@B15]). According to this second model, cells expressing mDμ are then unable to continue along the B cell pathway. Support for the active signaling model comes from three sets of observations: (*a*) that there is no counterselection in the absence of a Igμ transmembrane exon ([@B15]); (*b*) that there is no RF counterselection in the absence of syk ([@B18]); and (*c*) that there is no counterselection in early CD43^+^B220^+^ B cell precursors in the absence of λ5 ([@B33]). These experiments partially define the receptor structure for counterselection as composed of mDμ associated with λ5. Our observation that negative selection against Dμ does not occur in the absence of Igβ supports the signaling model, and identifies Igα-Igβ as the transducers that activate counterselection possibly by linking mDμ to nonreceptor tyrosine kinases.

Why does the expression of the Dμ pre-BCR lead to arrested development, whereas mature mIgμ in the same complex activates positive selection in early B cells? Both signals are produced in CD43^+^B220^+^ pre-B cells, both require λ5 ([@B33], [@B39], [@B42]), and the Igα-Igβ coreceptors ([@B19], [@B41]), and both are transmitted through a cascade that induces syk ([@B18], [@B43]). One way to explain the difference between the cellular response to mDμ pre-BCR and mIgμ pre-BCR expression might be an inability of Dμ to pair with conventional κ or λ Ig light chains ([@B14]). According to this model, cells expressing mDμ should be trapped in the CD43^−^B220^+^ preB cell compartment since B cell development can progress to the CD43^−^B220^+^ stage in the absence of conventional light chains ([@B44], [@B45]). However, elegant single cell sorting experiments have shown that mDμ-producing cells are selected against before this stage in CD43^+^B220^+^ pre-B cells ([@B33], [@B42]). Thus, the idea that abnormal pairing of mDμ with light chains is responsible for counterselection fails to take into account the observation that counterselection normally occurs independently of light chain gene rearrangements.

Two alternative explanations for the disparate cellular responses to the Dμ pre-BCR and the mIgμ pre-BCR are: (*a*) that there are qualitative differences between signals generated by a mDμ and a mIgμ receptor complex, and (*b*) pre-B-I cells that contain DJ~H~ rearrangements are in a different stage of differentiation than pre-B-II cells that have completed VDJ~H~ and express mIgμ ([@B8]). An example of two qualitatively distinct signals resulting in alternative biologic responses has been found in the highly homologous TCR receptor ([@B46], [@B47]). TCR interaction with ligand can produce either anergy or activation, depending on the affinity of the TCR for the peptide-MHC complex ([@B48]). High affinity ligands that produce T cell responses fully activate CD3 tyrosine phosphorylation, whereas peptides that induce anergy bind with low affinity and induce a reduced level of CD3 phosphorylation. The low level CD3 phosphorylation induced by the anergizing peptides is associated with less than optimal ZAP-70 kinase activation ([@B46], [@B47]).

Less is known about the physiologic responses activated by Igα-Igβ in developing B cells, but experiments in transgenic mice have shown that early B cell development requires tyrosine phosphorylation of Igβ ([@B20]), and by inference, receptor cross-linking. Although the cytoplasmic domains Igα and Igβ appear to have redundant functions in allelic exclusion and the pre-B cell transition ([@B20], [@B35]), neither Igα, ([@B41]) nor Igβ (Papavasiliou, N., and M.C. Nussenzweig, manuscript in preparation) alone are able to fully restore B cell development in the bone marrow, suggesting that there are specific functions for Igα and Igβ, or the IgαIgβ heterodimer. Biochemical support for the idea that individual coreceptors could have unique biologic functions also comes from transfection experiments in B cell lines ([@B49]--[@B51]) and from the observation that the cytoplasmic domains of Igα and Igβ bind to different sets of nonreceptor tyrosine kinases ([@B52]).

We would like to propose that positive and negative selection in developing B cells, like activation and anergy in T cells, may be mediated by differential phosphorylation of Igα and Igβ in the pre-BCR. Given the requirement for cross-linking in pre-BCR activation, the mechanism that produces the proposed differential phosphorylation of the mDμ and mIgμ pre-BCRs may be a function of their affinities for the cross-linker.
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^1^ *Abbreviations used in this paper:* BCR, B cell receptor; mIgμ, membrane immunoglobulin heavy chain; RF, reading frame.

![Flow cytometric analysis of spleen (*Spl*) and bone marrow cells (*BM*) from Igβ^−/−^, transgenic, and wild-type mice. Single-cell suspensions from lymphoid organs of 6-wkold mice were prepared and analyzed on FACScan^®^. Bone marrow cells were stained with PE--anti-B220 and FITC--anti-CD43. Spleen cells were stained with FITC--anti-IgM and PE-- anti-B220. The lymphocyte population was gated according to standard forward- and side-scatter values. The numbers in each quadrant represent the percentages of gated lymphocytes. *WT*, wild type; *RAG* ^−/−^, RAG-1 mutant; *Igβ* ^−/−^, Igβ mutant; *Igβ* ^−/−^ *μ.TG*, Igβ mutant, *mIgμ*, transgenic.](JEM.gong1){#F1}

![Ig gene rearrangements in Igβ^−/−^, transgenic, and wild-type mice. Bone marrow DNA from 6-wk-old mice was amplified with VH558L, VH7183 (not shown), or D~H~ and J~H~2 primers. Control primers were from the J-CH1 intervening sequence (*IVS*) ([@B22]).](JEM.gong2){#F2}

![Nucleotide sequences of D~H~--J~H~ joints from Igβ^−/−^ and wild-type sorted bone marrow B cells. D~H~ segment, N or P nucleotides, and J~H~4 segment sequences are shown. The number of DJ~H~4 joints in D~H~ RF 1, 2, or 3 are noted. Stop codons in D~H~ segments are underlined.](JEM.gong3){#F3}

![Nucleotide sequences of V(D)J (VH558L to DJH4) joints from Igβ^−/−^ and wild-type bone marrow B cells. D~H~ segment, N or P nucleotides, and J~H~4 segment sequences are shown. The number of DJ~H~4 joints in D~H~ RF 1, 2, or 3 are noted. Stop codons in D~H~ segments are underlined, and the D~H~ segments used (*S*) are indicated.](JEM.gong4){#F4}
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